IFRX

InflaRx N.V. Common Stock (IFRX)

Stock · NASDAQ · Health Care

$1.32as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 28, 2026

InflaRx to Host Virtual Capital Markets Day. InflaRx announced it will host a virtual Capital Markets Day. This event allows the company to present updates on its business and strategy to investors. The stock is currently trading near its 52-week low, with an RSI of 36.7 indicating recent weakness.

Active signals

200 SMA Touch84.6%
High Beta65.2%
Resistance level
$2.05
Industry
Biotechnology: Pharmaceutical Preparations

What IFRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike37-2.5%49%
Bollinger Band Breakout23-6.4%39%
200-Day Moving Average TouchActive now18+2.3%56%
Bollinger Band Breakdown16+9.9%75%
Any 20-session window (baseline)-0.9%47%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the trea…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
65

Fundamentals

1-day range
$1.43$1.53
Market cap
$124.34M
P/E (trailing)
—
P/E (forward)
-3.71
EPS (trailing)
$-0.35
Dividend yield
—
Beta
2.43
Avg. volume
759.6K
52-week range
$0.7984$2.95
Next earnings: November 9, 2026 · EPS estimate $-0.05confirmed

Forecasts

9 analyst ratings

Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$13.63
+936.6%
Median
$7.79
+492.3%
Low
$2.92
+122.1%

InflaRx N.V. Common Stock Competitors

Chosen by industry and closest market cap.

  • IFRX
    InflaRx N.V. Common Stock
    $1.32
    ▼ 8.33%
    Market cap $124.34MP/E —
    $0.7984$2.95
  • TLSA
    Tiziana Life Sciences Ltd. Common Shares
    $1.05
    ▲ 0.00%
    Market cap $123.99MP/E —
    $0.7615$2.2
  • GNLX
    Genelux Corporation Common Stock
    $2.42
    ▼ 2.42%
    Market cap $121.07MP/E —
    $2.29$8.54
  • SPRB
    Spruce Biosciences Inc. Common Stock
    $39.65
    ▼ 4.39%
    Market cap $127.76MP/E —
    $38.06$179.95
  • PMN
    ProMIS Neurosciences Inc. Common Shares (ON)
    $8.15
    ▼ 6.32%
    Market cap $119.54MP/E —
    $6.27$27.4
  • BGM
    BGM Group Ltd. Class A Ordinary Shares
    $8.65
    ▲ 0.70%
    Market cap $118.62MP/E —
    $6.45$303
  • YARW
    Yarrow Bioscience Inc. Common Stock
    $18.31
    ▼ 8.45%
    Market cap $116.71MP/E —
    $18.16$44.28

P/E shows — for peers not currently carrying a live signal of their own.

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.